Format

Send to

Choose Destination
Kidney Int. 2015 Jul;88(1):17-27. doi: 10.1038/ki.2015.59. Epub 2015 Mar 18.

Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Author information

1
Emory University School of Medicine, Atlanta, Georgia, USA.
2
Institute of Physiology, Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
3
University of Erlangen-Nürnberg, Erlangen, Germany.
4
University Medical Center Groningen, Groningen, The Netherlands.
5
PKD International, Geneva, Switzerland.
6
Juntendo University Graduate School of Medicine, Bunkyou, Tokyo, Japan.
7
Hennepin County Medical Center, Minneapolis, Minnesota, USA.
8
PKD Foundation, Kansas City, Missouri, USA.
9
University Health Network, University of Toronto, Toronto, Ontario, Canada.
10
Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA.
11
Université Catholique de Louvain, Brussels, Belgium.
12
University of Colorado, Denver, Colorado, USA.
13
Fundació Puigvert, REDinREN, Universitat Autónoma de Barcelona, Barcelona, Spain.
14
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
15
University of Maryland School of Medicine, Baltimore, Maryland, USA.
16
University College London, London, UK.

Abstract

Autosomal-dominant polycystic kidney disease (ADPKD) affects up to 12 million individuals and is the fourth most common cause for renal replacement therapy worldwide. There have been many recent advances in the understanding of its molecular genetics and biology, and in the diagnosis and management of its manifestations. Yet, diagnosis, evaluation, prevention, and treatment vary widely and there are no broadly accepted practice guidelines. Barriers to translation of basic science breakthroughs to clinical care exist, with considerable heterogeneity across countries. The Kidney Disease: Improving Global Outcomes Controversies Conference on ADPKD brought together a panel of multidisciplinary clinical expertise and engaged patients to identify areas of consensus, gaps in knowledge, and research and health-care priorities related to diagnosis; monitoring of kidney disease progression; management of hypertension, renal function decline and complications; end-stage renal disease; extrarenal complications; and practical integrated patient support. These are summarized in this review.

PMID:
25786098
PMCID:
PMC4913350
DOI:
10.1038/ki.2015.59
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center